Member Info for shepster

Hi SCHeckler, i hope he isn't going just to shoot ammo on the range, Lol

Hi PCS1954
Thanks again for making the effort, i was hoping to get a feel from you as to body language etc of the event but as it was shown on video this year you could get this from the online version as well so dont need to trouble you feeding back on this, onwards and upwards from here i hope, been a long time coming

Big shout out to all of the guys at the AGM, great questions and you all made the board open up and provide some decent feedback on what is going on and what they are trying to move forward, it has certainly helped my confidence, would have loved to have been there and shared a beer with you afterwards, hopefully next year we can all do this, thank you
Who was actually there, would be good to know the LSE names of all of the people there?

working okay for me but would agree Parker does look and sound very awkward fronting this meeting at the moment

Hi PCS1954, would you mind feeding back on your attendance at the meeting as i cant get there due to the train strike, would be good to know how the room feels as well as what is said, thanks for going, KR

Thanks all for taking the time to help my understanding, i did not want to vote down the wrong thing in ignorance.

i have received the paperwork to either attend AGM (which i cant due to rail strike) or to vote and return to broker. I am struggling to understand what point 5 on the ordinary resolution is and what it means in simple english, what exactly are the asking permission to do, can someone please help who has a better understanding than i do??

5. That the Directors be and they are generally and unconditionally authorised for the purposes of Section 551 of the
Companies Act 2006 (the Act) to exercise all the powers of the Company to allot shares in the Company and to grant
rights to subscribe for or convert any security into shares in the capital of the Company, up to an aggregate nominal
amount of £850,867 provided that this authority is for a period expiring at the conclusion of the Company’s next AGM,
but the Company may before such expiry make an offer or agreement which would or might require shares to be allotted
or such rights to be granted after such expiry and the Directors may allot shares and grant such rights in pursuance of
such offer or agreement, notwithstanding that the authority conferred by this resolution has expired. This authority is
in substitution for all earlier authorities, to the extent unused.

what will this be by the time of the AGM?

I am actually agreeing with you, i meant that everyone who holds is left to speculate on this issue as the RNS was so vague, i didn't mean to have a go at you, sorry it was a badly written post. GL

I have asked the board to answer what exactly the issue was/is with the CTA application as an official question for the agm, i have also asked them to comment on the success from their perspective of the consolidation as they pushed it to reduce share price volatility and attract institutional investors, neither of which have happened in my opinion, lets see if they can inform us on these issues as it would be good to know instead of speculate?

As a very LTH i have written to the company asking for a date for the AGM as like Andy i want to attend and look them in the eye about this and the consolidation which i personally did not go to plan, besides costing a lot of money with advisors and process and has achieved nothing positive. I as expected have heard nothing back but they will have to announce soon unless they intend to do this at arms length via investor online platform or similar again........

Would be nice to know who actually submitted the CTA, was it the company directly or the CRO, surely as others have suggested you would do a preliminary check to make sure all of the correct information was contained, this is where the company is losing my faith as they never communicate what is going on and what are the next steps etc

I would totally agree with your thoughts Basil, i still believe that we may come good eventually but it pains me to see things managed so badly in terms of methodology and PR etc, we are paying for advice and management from a lot of expensive people and do not appear to be making the right moves forwards, i too agree about the lack of new investors being very disappointing, come on Tim et al, we are worth better than this, i have invested in this for over 10 years now and don't want to fail at this stage of our development, they should be communicating with us a lot better

i am getting concerned how far this has now dropped, when will the market seem to see the positives everyone else is talking about...............................

i have asked has the placing achieved what the company expected and wanted?

I would like to hear the thoughts on this as it was sold very strongly to us?

you remind me so much of someone i used to work with in pharma so i always make sure i read your posts as i respected his opinion and i respect yours, thanks for all of your time to do what you do and i hope to meet up someday to put a face to the name, KR and GL

also now showing a large sell of 120k??

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Sareum notes proposed acquisition of Sierra Oncology by GSK

Cambridge, UK, 13 April 2022 - Sareum Holdings plc (AIM: SAR), the specialist drug development company, notes that Sierra Oncology, Inc ("Sierra"), the licence holder for SRA737 (a novel Chk1 inhibitor), has agreed to be acquired by GlaxoSmithKline plc ("GSK") for US$1.9 billion in cash. The transaction is expected to close in the third quarter of 2022 or before. GSK has noted that the key driver of the acquisition was momelotinib, a drug Sierra is developing for the treatment of myelofibrosis, which reported positive topline results in a Phase III study in January 2022.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed to Sierra in September 2016.

During the second half of 2021 and early 2022, Sierra noted it is finalising the design of several potential clinical trials to advance its pipeline candidates, including SRA737, which it said could start in 2022. These trials would investigate SRA737 in combination with other agents in haematologic and solid tumour indications.

Under an amended US$299m licensing deal on SRA737 between Sierra and CRT Pioneer Fund LP, Sareum is eligible to receive a 27.5% share of any future milestone payments as well as royalties on any future sales. The dosing of the first patient with SRA737 in any new clinical trial would result in a US$2.0m payment from Sierra, with 27.5% of this due to Sareum.

can i echo Mafuta's post as that was my thoughts exactly to save saying it twice, many thanks RMM, KR

chuckle brothers are alive and well and running audio for Sareum...........................